Although this study may not seem too much promising to cure MM by the use of Tivantinib as a single agent, the authors here suggest that it could represent an attractive option if combined with other anti-myeloma drugs such as proteasome inhibitors, since c-MET activation is often associated with clinical drug resistance in MM [91]. This evidence concerns the gene MET and plasma cell myeloma.